Every Form 4 that Balchem Corporation (BCPC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BCPC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCPC filings page.
Balchem Corporation senior executive Job Leonard van Gunsteren reported multiple equity compensation transactions. On February 11, 2026, he received 430 shares of restricted stock that vest over three years and 1,345 common shares from vesting performance stock units for the 2023–2025 performance period.
To cover tax obligations upon vesting, 756 shares were withheld at $178.68 per share on February 11 and 58 shares were withheld at $177.49 per share on February 12. He was also granted 1,600 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three. After these transactions he directly owns 10,149 common shares and 1,600 stock options.
Reid Martin Luther reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 7,900 shares at a weighted average price of $178.57 per share. Following the reported transactions, holdings were 9,073 shares.
Harris Theodore L reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 62,743 shares at a weighted average price of $178.58 per share. Following the reported transactions, holdings were 91,373 shares.
BCPC senior executive Graham George reported equity awards from the company. As SVP and Chief R&D Officer, he received a grant of 700 shares of common stock at a price of $0, increasing his directly held common stock to 3,200 shares, plus 20 shares held indirectly through a 401(k) plan.
The filing also shows a stock option grant for 2,600 shares of common stock with an exercise price of $178.68 per share, expiring on 02/11/2036. The restricted stock vests over three years (25%, 25%, 50%), while the options vest 20% in year one, 40% in year two, and 40% in year three.
Backus William A. reported multiple insider transaction types in a Form 4 filing for BCPC. The filing lists transactions totaling 4,889 shares at a weighted average price of $178.59 per share. Following the reported transactions, holdings were 6,736 shares.
BCPC senior vice president Frederic Boned reported new equity awards and related tax share withholdings. On February 11, he acquired 2,870 shares of restricted common stock and 2,247 common shares from performance stock units vesting for the 2023–2025 period.
To cover tax obligations, 1,151 of those vested shares were withheld at $178.68 per share on February 11 and an additional 203 shares were withheld at $177.49 per share on February 12. He was also granted stock options for 10,500 shares at a $178.68 exercise price, vesting over three years and expiring on February 11, 2036. After these transactions, he directly owned 8,978 common shares, plus 441 shares held indirectly in a 401(k) plan and 10,500 stock options.
BCPC senior vice president and Chief HR Officer Michael Brent Tignor reported multiple equity compensation transactions. On February 11, 2026, he acquired 1,200 shares of restricted common stock at $0, vesting over three years, and 1,929 shares from vested performance stock units for the 2023–2025 period, including 31 dividend equivalent shares.
To cover tax obligations on these vestings, 991 shares were withheld at $178.68 on February 11, 2026 and 165 shares were withheld at $177.49 on February 12, 2026. He also received a stock option for 4,400 shares at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three, expiring on February 11, 2036. Following these transactions he directly held 10,723 common shares, plus 1,456 shares indirectly through a 401(k) plan and 4,400 stock options.
BCPC executive Hatsuki Miyata, EVP, CLO & Secretary, reported several equity compensation transactions. On February 11, 2026, Miyata acquired 1,710 shares of common stock as restricted stock that vests over three years and 2,247 shares from performance stock units for the 2023–2025 period.
To cover related tax liabilities, 877 shares were withheld at $178.68 per share on February 11 and 181 shares were withheld at $177.49 per share on February 12. Miyata also received a grant of 6,300 stock options at an exercise price of $178.68, vesting 20% in year one, 40% in year two, and 40% in year three.
After these transactions, Miyata directly held 8,745 common shares and indirectly held 487 shares through a 401(k) plan, in addition to the 6,300 stock options.
Balchem Corporation executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported multiple equity compensation transactions and related tax withholdings. On February 11, 2026 he acquired 3,610 shares of common stock as restricted stock and 4,718 shares from vested performance stock units at no cost, while 2,416 of those vested units were withheld to satisfy tax obligations. He also received a stock option grant for 13,200 shares at an exercise price of $178.68 per share, vesting 20% in year one, 40% in year two, and 40% in year three, expiring in 2036. Additional shares were withheld on February 12, 2026 to cover taxes on previously granted restricted shares. After these transactions, he directly held 27,926 common shares, plus 1,086 shares held indirectly in a 401(k) plan, along with 13,200 stock options.
Rigaud Olivier, a director of issuer BCPC, reported an award of restricted common stock. On February 11, 2026, he acquired 870 shares at $0 per share as a grant, increasing his directly held common stock to 2,390 shares after the transaction.
The footnote explains that this restricted stock will vest in the reporting person one year after the grant date, and remains subject to transfer restrictions under a Restricted Stock Grant Agreement between the issuer and the director.
Balchem Corporation director Daniel E. Knutson reported an equity award of company stock. On 02/11/2026, he acquired 870 shares of Balchem common stock as a grant or award at a stated price of $0 per share, increasing his directly held stake to 6,899 shares.
The award is in the form of restricted stock that vests one year after the grant date. Until vesting, the shares are subject to transfer restrictions under a Restricted Stock Grant Agreement between Balchem and Knutson, meaning he must satisfy those conditions before the shares fully vest.
Kathleen B. Fish, a director of the issuer with ticker BCPC, received a grant of 870 shares of common stock on February 11, 2026. The filing classifies this as an acquisition of non-derivative securities at a price of $0 per share.
The 870 shares are restricted stock that will vest one year after the grant date, and are subject to transfer restrictions under a Restricted Stock Grant Agreement between the company and the director. Following this award, Fish beneficially owns 3,429 shares of common stock directly.
Wineinger Matthew David reported acquisition or exercise transactions in a Form 4 filing for BCPC. The filing lists transactions totaling 870 shares. Following the reported transactions, holdings were 8,012 shares.
CORP director David B. Fischer reported an acquisition of common stock through a restricted stock award. On February 11, 2026, he received 870 shares at a price of $0, characterized as a grant or award. These restricted shares vest in one year under a Restricted Stock Grant Agreement with the company. Following this transaction, Fischer directly holds 8,859 shares of CORP common stock.
Director Monica Vicente reported an acquisition of CORP common stock through an equity award. On February 11, 2026, she received 870 shares of restricted common stock at a stated price of $0 per share, increasing her direct holdings to 2,390 shares. According to the footnote, this restricted stock will vest in her name one year after the grant date and is subject to transfer restrictions set out in a Restricted Stock Grant Agreement between CORP and Vicente.
CORP vice president and chief accounting officer William A. Backus reported a routine tax-related share withholding. On 02/08/2026, 322 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 2/8/2023.
After this withholding, Backus beneficially owned 5,517 shares of CORP common stock directly and 283 shares indirectly through a 401(k) plan. The filing reflects administrative share withholding rather than an open-market sale.
BCPC’s executive vice president, chief legal officer, and secretary reported a routine tax-related share withholding. On 02/08/2026, 343 shares of common stock were disposed of at $173.16 per share to cover withholding taxes due upon vesting of restricted shares granted on 02/08/2023.
After this transaction, the officer beneficially owned 5,846 common shares directly and 487 common shares indirectly through a 401(k) plan.
An officer of the issuer with ticker BCPC, SVP and GM, Specialty Products Job Leonard van Gunsteren, reported a routine tax-related share withholding. On February 8, 2026, 258 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares granted on February 8, 2023.
After this withholding, van Gunsteren directly beneficially owns 9,188 shares of the company’s common stock. The transaction was coded “F,” indicating a tax withholding in connection with an equity award vesting rather than an open-market sale.
Backus William A., VP & Chief Accounting Officer of CORP (BCPC), reported a routine share withholding related to equity compensation. On 04/01/2025, 383 shares of common stock at $167.24 per share were withheld to cover taxes upon vesting of restricted shares granted on 4/1/2022.
After this transaction, he beneficially owned 5,839 common shares directly and 256 common shares indirectly through a 401(k) plan as of 4/1/2025. The report notes it was an inadvertent late filing caused by an administrative error.
Balchem Corporation’s Chairman, President & CEO Theodore L. Harris reported a tax-related share withholding in company stock. On 02/08/2026, 3,225 shares of common stock were withheld at $173.16 per share to cover withholding taxes upon vesting of restricted shares granted on 2/8/2023.
Following this transaction, Harris directly beneficially owns 75,934 shares of common stock. In addition, 2,007 shares are held indirectly through a 401(k) Plan. A further 1,022.58 shares are held in a trust for the benefit of his mother, where he serves as trustee and disclaims beneficial ownership except for any pecuniary interest.
BCPC senior vice president Frederic Boned reported a small tax‑related share withholding tied to equity compensation. On February 8, 2026, 430 shares of common stock were withheld at $173.16 per share to cover taxes on restricted shares granted on February 8, 2023. After this transaction, Boned directly owned 5,215 common shares and indirectly held 441 shares through a 401(k) plan.
BCPC executive Carl Martin Bengtsson, EVP & Chief Financial Officer, reported a routine tax-related share withholding. On February 8, 2026, 863 shares of common stock were withheld at $173.16 per share to cover taxes on vesting restricted shares granted on February 8, 2023.
After this transaction, Bengtsson beneficially owned 22,316 common shares directly and 1,086 common shares indirectly through a 401(k) plan. The filing reflects administrative settlement of equity compensation rather than an open-market sale.
Corp SVP Chief Supply Chain Officer Martin Luther Reid reported an administrative share withholding tied to equity compensation. On 02/08/2026, 416 shares of common stock were withheld at $173.16 per share to cover taxes due on the vesting of restricted shares originally granted on 02/08/2023.
After this transaction, Reid beneficially owns 6,975 common shares directly and 542 common shares indirectly through a 401(k) plan. The filing reflects tax settlement related to stock-based compensation rather than an open-market sale.
Balchem Corporation SVP & Chief HR Officer Michael Brent Tignor reported a routine tax-related share withholding transaction. On 02/08/2026, 373 shares of common stock were withheld at a price of $173.16 per share to cover taxes due upon vesting of restricted shares granted on 02/08/2023.
After this withholding, Tignor beneficially owned 8,750 shares of common stock directly and 1,456 shares indirectly through a 401(k) plan. The filing reflects administrative equity compensation activity rather than an open-market sale.
Balchem (BCPC) officer Martin Luther Reid, SVP Chief Supply Chain Officer, reported an open‑market sale of 1,200 shares of common stock on 11/11/2025 at $154.44 per share. Following the transaction, he beneficially owns 7,391 shares directly and 532 shares indirectly via a 401(k) plan.
Balchem (BCPC) disclosed an insider Form 4 for SVP/GM, Human Nutrition & Health, reporting a Code F transaction on 10/31/2025. The filing shows 1,085 shares of common stock were withheld at $153.39 per share to cover taxes upon vesting of restricted shares granted on 10/31/2022.
Following the transaction, the officer beneficially owns 5,645 shares directly and 415 shares indirectly via a 401(k) plan.
Balchem Corp (BCPC) reported that its SVP and Chief R&D Officer acquired 2,500 shares of common stock on 10/20/2025 via a restricted stock grant at $0 per share. Following the transaction, the reporting person beneficially owns 2,500 shares, held directly.
The award vests ratably over three years—25% on the first anniversary, 25% on the second, and 50% on the third—subject to transfer restrictions under a Restricted Stock Grant Agreement.